Development of pyridazinone derivatives linked ethyl-bridged-1,2,4-triazole for potential cancer therapy

Basit Öğe Kaydı
dc.contributor.authorMerde, Irem Bozbey
dc.contributor.authorAykac, Okan
dc.contributor.authorHepokur, Ceylan
dc.contributor.authorYasa, Yaren Zisa
dc.contributor.authorOnel, Gulce Taskor
dc.contributor.authorTurkmenoglu, Burcin
dc.date.accessioned2026-04-04T13:34:53Z
dc.date.available2026-04-04T13:34:53Z
dc.date.issued2026
dc.departmentİnönü Üniversitesi
dc.description.abstractA series of novel pyridazinone derivatives linked ethyl-bridged-1,2,4-triazole were synthesized starting from pchloroacetophenone. The chemical structures of the compounds 5(a-f) were identified by 1HNMR , 13CNMR and LC-QTOF-MS analysis. In this study, the DDPH method was used to evaluate the antioxidant properties of the compounds. The anticancer activity of the compounds was investigated by MTT method in MCF-7, MDA-MB-231 and L929 cell lines. Gene expression levels of Bcl2, Bax and Casp9 genes were compared, and stages of cell death were determined with high accuracy by flow cytometry. Since compound 5a showed promising cytotoxic effects, molecular docking study was performed to support these results and binding values against Bcl2 anti-apoptotic (PDB ID: 6QGG), Bcl-2 (PDB ID: 4IEH) and tubulin regulation (PDB ID: 1SA0) targets were calculated.
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUEBITAK 2209-A) [1919B012111441]
dc.description.sponsorshipThis study was funded by grants from The Scientific and Technological Research Council of Turkey (TUEBITAK 2209-A) (1919B012111441).
dc.identifier.doi10.1016/j.molstruc.2025.143827
dc.identifier.issn0022-2860
dc.identifier.issn1872-8014
dc.identifier.orcid0000-0002-5770-0847
dc.identifier.orcid0000-0002-7363-8801
dc.identifier.orcid0000-0002-9290-938X
dc.identifier.orcid0009-0000-7732-2428
dc.identifier.orcid0000-0001-6397-1291
dc.identifier.orcid0000-0002-9375-2329
dc.identifier.scopus2-s2.0-105014928109
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.molstruc.2025.143827
dc.identifier.urihttps://hdl.handle.net/11616/109478
dc.identifier.volume1349
dc.identifier.wosWOS:001569350500005
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Molecular Structure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectAnticancer activity
dc.subjectPyridazinone derivatives
dc.subjectMolecular docking
dc.subjectTriazole
dc.titleDevelopment of pyridazinone derivatives linked ethyl-bridged-1,2,4-triazole for potential cancer therapy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu